InvestorsHub Logo
Followers 144
Posts 27603
Boards Moderated 3
Alias Born 02/07/2004

Re: None

Tuesday, 10/12/2021 8:09:38 AM

Tuesday, October 12, 2021 8:09:38 AM

Post# of 3894
RedHill Biopharma shares rise after new U.S. patent for H. pylori infection treatment Talicia

Oct. 12, 2021 7:40 AM ETRedHill Biopharma Ltd. (RDHL)

By: Aakash Babu, SA News Editor

RedHill Biopharma (NASDAQ:RDHL) announces that the company has been granted a new U.S. patent covering Talicia, an approved medicine indicated for the treatment of H. pylori infection in adults.

The new patent reinforces the protection for Talicia through 2034, and the company plans to list the patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.

Talicia's all-in-one capsule comprising a proton pump inhibitor and two antibiotics was approved by the U.S. FDA in November 2019 for the treatment of H. pylori infection in adults.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDHL News